The Cancer Letter

The leading source for information on the issues that shape oncology since 1973

Clinical Roundup

Yale study identifies class of oncogenic fusions in lung and pancreatic cancer

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

Yale Cancer Center researchers have identified novel oncogenic gene fusions in lung and pancreatic cancer, as well as sarcoma. The fusions involve RASGRF1 (an activator of RAS signaling) and promote cellular changes leading to tumor development. 

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

Clinical Roundup

Zoldonrasib + daraxonrasib show 81% ORR in patients with RAS G12D metastatic pancreatic cancer, phase I/II study finds

Zoldonrasib, an oral RAS(ON) G12D-selective covalent inhibitor, in combination with daraxonrasib showed 81% objective response rate compared to zoldonrasib in combination with standard of care chemotherapy in previously untreated patients with RAS G12D metastatic pancreatic ductal adenocarcinoma, according to results of two phase I/II study. 
Table of Contents

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account